stocks logo

EBS

Emergent BioSolutions Inc
$
6.070
-0.43(-6.615%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
6.640
Open
6.620
VWAP
6.21
Vol
1.59M
Mkt Cap
329.47M
Low
5.985
Amount
9.87M
EV/EBITDA(TTM)
14.29
Total Shares
52.40M
EV
846.07M
EV/OCF(TTM)
7.68
P/S(TTM)
0.35
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
146.37M
-42.53%
--
--
212.70M
-27.6%
--
--
240.70M
+23.63%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Emergent BioSolutions Inc. (EBS) for FY2025, with the revenue forecasts being adjusted by -0.51% over the past three months. During the same period, the stock price has changed by 23.37%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.51%
In Past 3 Month
EPS Estimates for FY2024
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+23.37%
In Past 3 Month
2 Analyst Rating
up Image
122.41% Upside
Wall Street analysts forecast EBS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EBS is 13.50 USD with a low forecast of 12.00 USD and a high forecast of 15.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
up Image
122.41% Upside
Current: 6.070
sliders
Low
12.00
Averages
13.50
High
15.00
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$15
2025-04-01
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$15
2025-03-21
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$15
2025-03-04
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$15
2025-01-21
Reason
Hikma Pharmaceuticals (HKMPF) announces that it has entered an exclusive commercial partnership with Emergent BioSolutions (EBS) for the sale of Kloxxado naloxone HCl nasal spray 8 mg in the U.S. and Canada. Kloxxado was approved by the U.S. FDA in April 2021 for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients. Emergent distributes Narcan Nasal Spray 4 mg, which is the first FDA-approved over-the-counter naloxone product for the emergency treatment of opioid overdose.
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$15
2025-01-10
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Initiates
$15
2024-12-30
Reason

Valuation Metrics

The current forward P/E ratio for Emergent BioSolutions Inc (EBS.N) is 10.24, compared to its 5-year average forward P/E of 14.70. For a more detailed relative valuation and DCF analysis to assess Emergent BioSolutions Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
14.70
Current PE
10.24
Overvalued PE
51.38
Undervalued PE
-21.98

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-669.36
Current EV/EBITDA
6.36
Overvalued EV/EBITDA
2388.30
Undervalued EV/EBITDA
-3727.03

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
1.10
Current PS
0.42
Overvalued PS
2.05
Undervalued PS
0.14

Financials

Annual
Quarterly
FY2025Q1
YoY :
-26.03%
222.20M
Total Revenue
FY2025Q1
YoY :
+30.28%
51.20M
Operating Profit
FY2025Q1
YoY :
+655.56%
68.00M
Net Income after Tax
FY2025Q1
YoY :
+600.00%
1.19
EPS - Diluted
FY2025Q1
YoY :
-79.84%
-14.80M
Free Cash Flow
FY2025Q1
YoY :
+16.81%
60.58
Gross Profit Margin - %
FY2025Q1
YoY :
-183.73%
9.78
FCF Margin - %
FY2025Q1
YoY :
+920.00%
30.60
Net Margin - %
FY2025Q1
N/A
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
49.4K
USD
1
3-6
Months
261.4K
USD
2
6-9
Months
0.0
USD
0
0-12
Months
443.8K
USD
2
Bought
0-3
1
349.8K
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
61.6K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
16.0K
USD
2
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

EBS News & Events

Events Timeline

2025-07-28 (ET)
2025-07-28
08:54:59
Emergent BioSolutions announces publication on brincidofovir in Mpox
select
2025-07-28
08:51:59
Emergent BioSolutions 'applauds' OTC naloxone availability in U.S. House
select
2025-07-08 (ET)
2025-07-08
16:49:40
Emergent BioSolutions secures $51.9M contract modification
select
Sign Up For More Events

News

9.5
07-15Newsfilter
Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025
6.5
07-11NASDAQ.COM
Peek Under The Hood: XBI Has 57% Upside
6.0
07-08SeekingAlpha
Emergent BioSolutions signs contract modification award for CNJ-016
Sign Up For More News

FAQ

arrow icon

What is Emergent BioSolutions Inc (EBS) stock price today?

The current price of EBS is 6.07 USD — it has decreased -6.62 % in the last trading day.

arrow icon

What is Emergent BioSolutions Inc (EBS)'s business?

arrow icon

What is the price predicton of EBS Stock?

arrow icon

What is Emergent BioSolutions Inc (EBS)'s revenue for the last quarter?

arrow icon

What is Emergent BioSolutions Inc (EBS)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Emergent BioSolutions Inc (EBS)'s fundamentals?

arrow icon

How many employees does Emergent BioSolutions Inc (EBS). have?

arrow icon

What is Emergent BioSolutions Inc (EBS) market cap?